Clinical Trial Update: Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Acasunlimab alone and in combination with pembrolizumab for advanced melanoma that has relapsed after prior checkpoint inhibitor ther…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma
• Unresectable Melanoma

Drugs mentioned

• Acasunlimab (acasunlimab)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Genmab | Conditions: Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID) | Phase 2 | Status: ACTIVE_NOT_RECRUITING